In the pulsating world of biotech, we’re often reminded of the adage: ‘The only constant is change.’ Nowhere is this clearer than in the paradigm-shifting developments in the field of lymphoma treatment, spearheaded by the trailblazing team at Lyell Immunopharma. The company’s intrepid CEO and president, Lynn Seely, recently revealed exciting new clinical data from […]
Category: B-Cell Receptor
Advancements in STARLIGHT-1 B-Cell NHL Trial
In a significant stride forward for targeted cancer treatments, Estrella Immunopharma has announced an encouraging milestone in their groundbreaking STARLIGHT-1 trial. The trial, which aims to evaluate the safety, efficacy, and potential of EB103, a novel CD19-redirected Artemis T-cell therapy, has successfully dosed the first patient in its second cohort. This innovative therapy is targeted […]
